Matches in Wikidata for { <http://www.wikidata.org/entity/Q92745332> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q92745332 description "artículu científicu espublizáu en mayu de 2019" @default.
- Q92745332 description "im Mai 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92745332 description "scientific article published on 01 May 2019" @default.
- Q92745332 description "wetenschappelijk artikel" @default.
- Q92745332 description "наукова стаття, опублікована 1 травня 2019" @default.
- Q92745332 description "գիտական հոդված հրատարակված 2019 թվականի մայիսի 1-ին" @default.
- Q92745332 name "Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab" @default.
- Q92745332 name "Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab" @default.
- Q92745332 type Item @default.
- Q92745332 label "Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab" @default.
- Q92745332 label "Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab" @default.
- Q92745332 prefLabel "Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab" @default.
- Q92745332 prefLabel "Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab" @default.
- Q92745332 P1433 Q92745332-CA6670FE-0C4B-40C5-AC8B-9257C1EAB232 @default.
- Q92745332 P1476 Q92745332-E011AF7B-E1FD-4CC0-AB03-A59EE09EC15F @default.
- Q92745332 P2093 Q92745332-4C0CD17B-995C-45F9-8F5C-66F8DCF16437 @default.
- Q92745332 P2093 Q92745332-FE53334E-FFCD-48EB-8A0E-9D31865651F4 @default.
- Q92745332 P304 Q92745332-CBFD4434-326D-49DA-AF0E-45A8DCCDE547 @default.
- Q92745332 P31 Q92745332-5FD2A4B3-7390-4163-A5F0-3A96D04ABA5F @default.
- Q92745332 P356 Q92745332-4EF7C80C-3458-4FB9-8A3F-70B80FD2FB7A @default.
- Q92745332 P433 Q92745332-DE97D4A2-88AC-4CCB-95CD-01F3BDDC50C3 @default.
- Q92745332 P478 Q92745332-3682F37E-8054-4EB3-8E3A-17323A121DE5 @default.
- Q92745332 P577 Q92745332-EF32FAE6-9293-41FE-A5D1-0B632831395A @default.
- Q92745332 P698 Q92745332-57B03F4D-A5F8-4D90-A60C-E5C672BB4C69 @default.
- Q92745332 P921 Q92745332-CF248B5A-BB4D-4523-A39D-5C7D3DCB5CDC @default.
- Q92745332 P356 CJI.0000000000000265 @default.
- Q92745332 P698 30933044 @default.
- Q92745332 P1433 Q15763946 @default.
- Q92745332 P1476 "Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab" @default.
- Q92745332 P2093 "Keisuke Shirai" @default.
- Q92745332 P2093 "Muhammad Z Afzal" @default.
- Q92745332 P304 "136-141" @default.
- Q92745332 P31 Q13442814 @default.
- Q92745332 P356 "10.1097/CJI.0000000000000265" @default.
- Q92745332 P433 "4" @default.
- Q92745332 P478 "42" @default.
- Q92745332 P577 "2019-05-01T00:00:00Z" @default.
- Q92745332 P698 "30933044" @default.
- Q92745332 P921 Q13896859 @default.